TY - JOUR
T1 - Low-density lipoprotein (LDL) levels and risk of arterial occlusive events in chronic myeloid leukemia patients treated with nilotinib
AU - Caocci, Giovanni
AU - Mulas, Olga
AU - Capodanno, Isabella
AU - Bonifacio, Massimiliano
AU - Annunziata, Mario
AU - Galimberti, Sara
AU - Luciano, Luigiana
AU - Tiribelli, Mario
AU - Martino, Bruno
AU - Castagnetti, Fausto
AU - Binotto, Gianni
AU - Pregno, Patrizia
AU - Stagno, Fabio
AU - Abruzzese, Elisabetta
AU - Bocchia, Monica
AU - Gozzini, Antonella
AU - Albano, Francesco
AU - Fozza, Claudio
AU - Luzi, Debora
AU - Efficace, Fabio
AU - Simula, Maria Pina
AU - Scaffidi, Luigi
AU - Baratè, Claudia
AU - De Gregorio, Fiorenza
AU - Stella, Rossella
AU - Gugliotta, Gabriele
AU - Pirillo, Francesca
AU - Trawinska, Malgorzata Monika
AU - Sicuranza, Anna
AU - Cattaneo, Daniele
AU - Attolico, Immacolata
AU - Scalzulli, Emilia
AU - Iurlo, Alessandra
AU - Foà, Robin
AU - Breccia, Massimo
AU - La Nasa, Giorgio
N1 - Funding Information:
This article was carried out within the framework of the research project financed by P.O.R. SARDEGNA F.S.E. 2014–2020 - Asse III “Istruzione e Formazione, Obiettivo Tematico: 10, Obiettivo Specifico: 10.5, Azione dell’accordo fi Partenariato:10.5.12 “Avviso di chiamata per il finanziamento di Progetti di ricerca – Anno 2017”.
Publisher Copyright:
© 2021, The Author(s), under exclusive licence to Springer-Verlag GmbH, DE part of Springer Nature.
Copyright:
Copyright 2020 Elsevier B.V., All rights reserved.
PY - 2021
Y1 - 2021
N2 - Recommendations for dyslipidemia management aimed at reducing arterial occlusive events (AOEs) have been recently published. So far, no data have been reported on the management of dyslipidemia in chronic myeloid leukemia (CML) patients treated with nilotinib. We investigated 369 CML adult patients, stratified according to the new Systematic Coronary Risk Evaluation (SCORE) scoring system. Plasma levels of cholesterol, HDL, LDL, and triglycerides were measured prior to the start of nilotinib and after 3, 6, and 12 months. The 5-year cumulative incidence of AOEs was 15.9%. Patients with cholesterol levels > 200 mg/dL and LDL > 70 mg/dL 3 months after treatment showed a significantly higher incidence of AOEs (21.9 ± 4.6% vs 6.2 ± 2.5, P = 0.003). Patients belonging to the high and very high SCORE risk group showed a significant increase of AOEs (34.4 ± 6% vs 10 ± 2.1%, P < 0.001). In multivariate analysis, both high cholesterol and LDL levels and a high and very high SCORE risk remained significantly associated with the risk of AOEs (P = 0.008; HR = 3.5; 95% CI = 1.4–8.7 and P < 0.001; HR = 4.4; 95% CI = 2–9.8, respectively). Overall, 78 patients (21.1%) presented dyslipidemia at the time of CML diagnosis and 88 (23.3%) after starting nilotinib, but only 26 of them (29.5%) were treated with statins. Low LDL and cholesterol plasma levels are associated with a significant lower risk of AOEs in CML patients treated with nilotinib in the real life.
AB - Recommendations for dyslipidemia management aimed at reducing arterial occlusive events (AOEs) have been recently published. So far, no data have been reported on the management of dyslipidemia in chronic myeloid leukemia (CML) patients treated with nilotinib. We investigated 369 CML adult patients, stratified according to the new Systematic Coronary Risk Evaluation (SCORE) scoring system. Plasma levels of cholesterol, HDL, LDL, and triglycerides were measured prior to the start of nilotinib and after 3, 6, and 12 months. The 5-year cumulative incidence of AOEs was 15.9%. Patients with cholesterol levels > 200 mg/dL and LDL > 70 mg/dL 3 months after treatment showed a significantly higher incidence of AOEs (21.9 ± 4.6% vs 6.2 ± 2.5, P = 0.003). Patients belonging to the high and very high SCORE risk group showed a significant increase of AOEs (34.4 ± 6% vs 10 ± 2.1%, P < 0.001). In multivariate analysis, both high cholesterol and LDL levels and a high and very high SCORE risk remained significantly associated with the risk of AOEs (P = 0.008; HR = 3.5; 95% CI = 1.4–8.7 and P < 0.001; HR = 4.4; 95% CI = 2–9.8, respectively). Overall, 78 patients (21.1%) presented dyslipidemia at the time of CML diagnosis and 88 (23.3%) after starting nilotinib, but only 26 of them (29.5%) were treated with statins. Low LDL and cholesterol plasma levels are associated with a significant lower risk of AOEs in CML patients treated with nilotinib in the real life.
KW - Arterial occlusive event
KW - Cholesterol
KW - Chronic myeloid leukemia
KW - LDL
KW - Nilotinib
KW - Triglycerides
UR - http://www.scopus.com/inward/record.url?scp=85098665618&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85098665618&partnerID=8YFLogxK
U2 - 10.1007/s00277-020-04392-w
DO - 10.1007/s00277-020-04392-w
M3 - Article
AN - SCOPUS:85098665618
JO - Ann. Hematol.
JF - Ann. Hematol.
SN - 0939-5555
ER -